RECRUITING

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.

Official Title

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

Quick Facts

Study Start:2024-10-17
Study Completion:2026-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06621329

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Acute subarachnoid hemorrhage
  2. * Age greater than 18 years
  3. * Secured aneurysm
  4. * Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision
  5. * maker
  6. * Patient or surrogate decision maker is available to consent
  1. * Less than 18 years old
  2. * Unsecured aneurysm
  3. * Pregnant or lactating
  4. * Prisoner
  5. * Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker
  6. * Nasal or facial trauma or surgery within the last three months
  7. * Allergy to lidocaine, bupivacaine, or dexamethasone
  8. * Patient is unable to consent and no available surrogate decision maker

Contacts and Locations

Study Contact

Janice Wang-Polagruto, PhD, CCRP
CONTACT
916-551-3244
jfwang@ucdavis.edu
Ryan Martin, MD
CONTACT
916-734-4300
rymartin@ucdavis.edu

Principal Investigator

Christine Picinich, MS, AGACNP-BC, CCRN
PRINCIPAL_INVESTIGATOR
University of California, Davis

Study Locations (Sites)

UC Davis Medical Center
Sacramento, California, 95817
United States

Collaborators and Investigators

Sponsor: University of California, Davis

  • Christine Picinich, MS, AGACNP-BC, CCRN, PRINCIPAL_INVESTIGATOR, University of California, Davis

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-17
Study Completion Date2026-10

Study Record Updates

Study Start Date2024-10-17
Study Completion Date2026-10

Terms related to this study

Keywords Provided by Researchers

  • aSAH
  • peripheral nerve block
  • sphenopalatine ganglion
  • subarachnoid hemorrhage
  • headache

Additional Relevant MeSH Terms

  • SAH (Subarachnoid Hemorrhage)
  • Headache